Get the Stockscreener App
20.27
0.83%
-0.17
Damora Therapeutics Inc stock is traded at $20.27, with a volume of 875.18K.
It is down -0.83% in the last 24 hours and down -33.12% over the past month.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
See More
Previous Close:
$20.44
Open:
$20.38
24h Volume:
875.18K
Relative Volume:
1.36
Market Cap:
$1.25B
Revenue:
-
Net Income/Loss:
$-209.84M
P/E Ratio:
-4.4354
EPS:
-4.57
Net Cash Flow:
$-6.73M
1W Performance:
-11.02%
1M Performance:
-33.12%
6M Performance:
-15.26%
1Y Performance:
+0.00%
1-Day Range:
$19.39
$20.73
1-Week Range:
$19.39
$23.44
52-Week Range:
$16.50
$34.89
Damora Therapeutics Inc Stock (DMRA) Company Profile
Name
Damora Therapeutics Inc
Sector
Industry
Phone
(781) 281-9020
Address
221 CRESCENT STREET, WALTHAM
Compare DMRA vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
20.27 | 1.25B | 0 | -209.84M | -6.73M | -4.57 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Initiated | RBC Capital Mkts | Outperform |
| Mar-25-26 | Initiated | Evercore ISI | Outperform |
| Feb-17-26 | Initiated | UBS | Buy |
| Jan-07-26 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Initiated | Guggenheim | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | BofA Securities | Buy |
| Nov-23-20 | Initiated | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | SVB Leerink | Outperform |
View All
Damora Therapeutics Inc Stock (DMRA) Latest News
Damora Therapeutics: Potential Payday Is A Long Way Off (NASDAQ:DMRA) - Seeking Alpha
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Damora (DMRA) Update: Gains 1.68% to Reach $30.82 in the Current Update; Price Setup: the Near-Term Reference Band Stretches From $29.28 to $32.36 on the DayStrong Buy Stocks - vinanet.vn
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
Damora (DMRA) Results at a Glance: The Available Earnings Metric Delivers a Miss in the Current Update; Session Move: The Share Price Sheds 6.23% in Latest TradingEarnings Decline Risk - vinanet.vn
DAMORA THERAPEUT (DMRA) Stock News, Mar 19-23, 2026 - Stock Titan
Damora Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Damora Therapeutics (DMRA) Is Up 5.1% After Starting CLARITY-101 mutCALR Trial Has The Bull Case Changed? - simplywall.st
Damora Therapeutics (DMRA) Starts CLARITY 101 Trial With Valuation Still In Focus - Sahm
Damora Therapeutics (DMRA) Adds 1.01% as Bulls Defend Key Support ZoneVolatility Smirk - vinanet.vn
Damora Therapeutics (DMRA) Advances 1.01% to $31.04 as Biotech Sentiment SteadiesKAMA Signal - dars.gov.et
Damora Therapeutics Director Andrew Cheng Granted Stock Options for 30,350 Shares - Kalkine Media
Damora Therapeutics (DMRA) director awarded 30,350 stock options at $31.00 strike - Stock Titan
Damora Therapeutics (DMRA) files Form 3 for new director Andrew Cheng - Stock Titan
DMRA Q1 2026 Earnings: EPS Misses Estimates by 56.8% as Shares Rise 8%Fiscal Year Earnings - vinanet.vn
Equities Analysts Offer Predictions for DMRA Q3 Earnings - MarketBeat
Damora Therapeutics, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
Damora Therapeutics: Competition Validates The Target While Its Portfolio Creates The Upside - Seeking Alpha
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
DMRA SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus
Damora Therapeutics Q2 Results: Net Loss Widens To $31.2 Million - scanx.trade
Damora Therapeutics Q2 Results: EPS beats estimate, losses narrow - scanx.trade
Damora Therapeutics (NASDAQ: DMRA) resets $150M ATM after Cayman redomestication - Stock Titan
Damora Therapeutics, Inc. SEC Filing (Aug 10, 2026) - Stock Titan
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Damora Starts DMR-001 Trial With 100 mg Monthly Dose - Stock Titan
Damora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - MarketBeat
Does CLARITY-101’s mutCALR Antibody Launch Change The Bull Case For Damora Therapeutics (DMRA)? - simplywall.st
DMRA Q1 2026 Earnings: Wider-than-Expected Loss Signals Rising Clinical-Stage Cost PressuresPositive Surprise Momentum - dars.gov.et
Damara (DMRA): Lori Firmani plans sale of 1,800 common shares via Maxim - Stock Titan
Damora Therapeutics, Inc. Common Stock (DMRA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - marketbeat.com
Damora initiates phase 1 trial of mutCALR antibody therapy - Investing.com
Damora initiates phase 1 trial of mutCALR antibody therapy By Investing.com - Investing.com Australia
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis - The Manila Times
Damora Begins Testing Antibody Designed for Monthly Doses - Stock Titan
Damora Therapeutics earnings on deck as rare blood cancer race heats up - Investing.com India
Damora Therapeutics grants 451,000 stock options to six new hires - scanx.trade
DMRA Q1 2026 Earnings: EPS Misses by 56.8% as Loss Widens, Shares SlipROE Trend Analysis - careplusvn.com
Damora Therapeutics (DMRA) Edges Higher at $29.37 as Traders Eye Key Resistance at $30.84Fade Trade - dars.gov.et
Wedbush Increases Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Price Target to $40.00 - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) to Post Earnings on Wednesday - MarketBeat
BlackRock (DMRA holder) reports 3.14M Damora Therapeutics shares in new ownership filing - Stock Titan
DMRA Initiates Coverage On Jefferies -- Rating Set to Buy, PT at $50 - GuruFocus
Jefferies Initiates Coverage on Damora Therapeutics With Buy Rating, $50 Price Target - marketscreener.com
H.C. Wainwright reiterates Damora Therapeutics stock rating on device advantage - Investing.com Canada
This Damora Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Jefferies initiates Damora Therapeutics stock with buy rating By Investing.com - Investing.com Canada
Damora Therapeutics Inc Stock (DMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):